| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Taysha Gene Therapies, Inc. (TSHA) has 8 insiders with recent SEC Form 4 filings, including 2 buys and 7 sells. TSHA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 2.84M | $19.35M | - | |
| CFO | 1.44M | $9.82M | - | |
| Dir | 1.16M | $7.87M | - | |
| Pres | 1.12M | $7.61M | - | |
| CEO | 648.0K | $4.41M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2021 | Prasad Suyash90 | CMO And Head Of R&D | Sell | 79,000 | $22.63 | $1,787,935.64 | -1.8% | -8.9% | -83.6% | |
| May 20, 2021 | Nolan Sean P. | Director | Buy | 1,170 | $22.35 | $26,149.50 | New | -21.5% | -87.2% | |
| May 14, 2021 | Manning Paul B53 | Director, 10% Owner | Buy | 12,000 | $20.98 | $251,760.00 | New | -16.6% | -83.6% |